Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR01687
|
|||||
| Drug Name |
Sitafloxacin
|
|||||
| Synonyms |
Sitafloxacin; Gracevit; Sitafloxacin Sesquihydrate; UNII-3GJC60U4Q8; Sitafloxacin isomer II; DU-6859a; C19H18ClF2N3O3; 3GJC60U4Q8; 7-((S)-7-AMINO-5-AZASPIRO[2.4]HEPTAN-5-YL)-8-CHLORO-6-FLUORO-1-((1R,2S)-2-FLUOROCYCLOPROPYL)-4-OXO-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID; STFX; 7-[(7S)-7-amino-5-azaspiro[2.4]heptan-5-yl]-8-chloro-6-fluoro-1-[(1R,2S)-2-fluorocyclopropyl]-4-oxo-quinoline-3-carboxylic acid
|
|||||
| Indication | Escherichia Coli Infections [ICD11: 1A03] | Phase 2/3 | [1] | |||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C19H18ClF2N3O3
|
|||||
| Canonical SMILES |
C1CC12CN(CC2N)C3=C(C=C4C(=C3Cl)N(C=C(C4=O)C(=O)O)C5CC5F)F
|
|||||
| InChI |
InChI=1S/C19H18ClF2N3O3/c20-14-15-8(17(26)9(18(27)28)5-25(15)12-4-10(12)21)3-11(22)16(14)24-6-13(23)19(7-24)1-2-19/h3,5,10,12-13H,1-2,4,6-7,23H2,(H,27,28)/t10-,12+,13+/m0/s1
|
|||||
| InChIKey |
PNUZDKCDAWUEGK-CYZMBNFOSA-N
|
|||||
| CAS Number |
CAS 127254-12-0
|
|||||
| Pharmaceutical Properties | Molecular Weight | 409.8 | Topological Polar Surface Area | 86.9 | ||
| Heavy Atom Count | 28 | Rotatable Bond Count | 3 | |||
| Hydrogen Bond Donor Count | 2 | Hydrogen Bond Acceptor Count | 8 | |||
| XLogP |
0.7
|
|||||
| PubChem CID | ||||||
| ChEBI ID |
CHEBI:4304
|
|||||
| DT(s) Transporting This Drug | P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | |
| References | ||||||
| 1 | ClinicalTrials.gov (NCT02729116) Sitafloxacin and Ertapenem Treatment for Acute Urinary Tract Infection Caused by E. Coli or K. Pneumoniae in Post-kidney Transplantation Patients | |||||
| 2 | Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.